Pathological biomarkers such as estrogen receptor (ER), progesterone receptor (PgR), ErbB2, Ki‐67, cytokeratins, and epidermal growth factor (EGF) receptor are mainly used in clinical situations to define breast cancer subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.